Eloxx doses first patients in Alport syndrome trial, clears IND for ADPKD studyNov 16Quarterly updateEloxx Pharmaceuticals, Inc.
Eloxx adds Geno Germano to board, finalizes Phase 2 trial design for exaluren in ADPKDOct 21PeopleEloxx Pharmaceuticals, Inc.exaluren
Eloxx reports Q2 2026 results after $66 million raise and Nasdaq uplistingAug 11Quarterly updateEloxx Pharmaceuticals, Inc.